- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06031948
pBFS-guided Noninvasive Neuromodulation for Pre-school Children With ASD
Personalized Brain Functional Sectors (pBFS) Guided Noninvasive Neuromodulation Treatment for Pre-school Children With Autism Spectrum Disorder (ASD): a Single-center, Double-blinded, Sham-Controlled, Randomized Clinical Trial Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Autism spectrum disorder is a neurodevelopmental disorder, begins early in life. Using the personalized brain functional sectors (pBFS) technology, investigators could precisely identify individualized brain function networks based on the functional MRI scan. For each participant, two personalised TMS intervention targets will be chosen by blinded researcher. One executive function network target is located in the dorsal lateral prefrontal cortex (DLPFC) , and the other social function network target is located in the dorsal medial prefrontal cortex (DMPFC).
The participants will be equally randomized to the following four groups, active iTBS to the left DMPFC or the left DLPFC, and sham iTBS to either the left DMPFC or left DLPFC at a ratio of 2:2:1:1. Later analyses will combine the two sham groups as one control group. Each participant will receive 1800 pulse active or sham iTBS (100% RMT) in each session, 3 sessions daily, 5 days per week for 8 weeks, as well as background behavioral training between iTBS sessions. Pre-and post-treatment functional MRI data will be collected under sedation.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Qi Liu, Ph.D.
- Phone Number: 010-80726688
- Email: a0000153@cpl.ac.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 2.5-6 years old
- Have the diagnosis of autism spectrum disorder
- ADOS-2 score is higher than the ASD cut-offs
- Capacity to follow the study procedures, including fMRI scan under sedation, assessment, and rehabilitation training
- Participant's parents or other legal guardians give informed consent
Exclusion Criteria:
- Current or history of psychotic disorders, such as schizophrenia, schizoaffective disorder, bipolar disorder
- Severe self-injury or suicidal behavior presented in the last 1 year
- Severe visual, auditory, or motor disability that interferes with any study procedure
- Current, history or family history of epilepsy
- Known severe physical diseases, such as congenital heart defect, traumatic brain injury
- Metal implantations, which are contradicted by MRI or TMS, such as artificial cardiac pacemakers, stents, cochlear implants
- Received TMS, tCS, FUS, or other neuromodulation treatment in the last 3 months
- Currently participating in other clinical trials
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DLPFC group
Active iTBS will be delivered to the left DLPFC.
|
Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
|
Experimental: DMPFC group
Active iTBS will be delivered to the left DMPFC.
|
Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
|
Sham Comparator: Sham to DMPFC group
Sham iTBS will be delivered to the left DMPFC.
|
Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
|
Sham Comparator: Sham to DLPFC group
Sham iTBS will be delivered to the left DLPFC.
|
Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ADOS-2 SA change
Time Frame: Pre-treatment (baseline), immediately post-treatment
|
The social affect (SA) dimension score change of autism diagnostic observation scale, 2nd edition (ADOS-2) from baseline.
Higher scores mean a worse outcome.
|
Pre-treatment (baseline), immediately post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ADOS-2 total score change
Time Frame: Pre-treatment (baseline), immediately post-treatment
|
The total score change of autism diagnostic observation scale, 2nd edition (ADOS-2) from baseline.
Higher scores mean a worse outcome.
|
Pre-treatment (baseline), immediately post-treatment
|
CBCL score change
Time Frame: Pre-treatment (baseline), immediately post-treatment
|
Score change of the child behavior checklist (CBCL) from baseline.
Higher scores mean a worse outcome.
|
Pre-treatment (baseline), immediately post-treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SRS-2 score change
Time Frame: Pre-treatment (baseline), immediately post-treatment
|
Score change of the Social Responsiveness Scale, 2nd edition (SRS-2) from baseline.
Higher scores mean a worse outcome.
|
Pre-treatment (baseline), immediately post-treatment
|
SCQ score change
Time Frame: Pre-treatment (baseline), immediately post-treatment
|
Score change of the Social Communication Questionnaire (SCQ) from baseline.
Higher scores mean a worse outcome.
|
Pre-treatment (baseline), immediately post-treatment
|
RBS-R score change
Time Frame: Pre-treatment (baseline), immediately post-treatment
|
Score change of the Repetitive Behavior Scale-Revised (RBS-R) from baseline.
Higher scores mean a worse outcome.
|
Pre-treatment (baseline), immediately post-treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Hesheng Liu, Ph.D., Changping Laboratory
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CPLASD2023HNC50
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hoffmann-La RocheActive, not recruitingAutism Spectrum Disorder (ASD)United States, Canada, Italy, Spain
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand
-
Technion, Israel Institute of TechnologyCompleted
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAutism | Autism Spectrum Disorder (ASD)United States
-
Corporacion Parc TauliUnknown
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
Florida Gulf Coast UniversityCompletedAutism Spectrum Disorder High-FunctioningUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
National Taiwan University HospitalCompletedAutism Spectrum Disorder High-FunctioningTaiwan
Clinical Trials on active iTBS
-
Central South UniversityRecruitingSuicidal Ideation | Suicide and Self-harm | Non Suicidal Self InjuryChina
-
Changping LaboratoryChina Rehabilitation Research CenterRecruiting
-
Central South UniversityRecruitingBipolar Depression | Major Depressive DisorderChina
-
Centre for Addiction and Mental HealthUniversity Health Network, Toronto; University of British ColumbiaRecruiting
-
Changping LaboratoryChina Rehabilitation Research CenterRecruiting
-
Northwell HealthUniversity of Maryland, Baltimore; Centre for Addiction and Mental Health; Wellcome...RecruitingSchizophrenia | Schizo Affective Disorder | Schizophreniform Disorders | Psychosis Nos/OtherUnited States
-
University of British ColumbiaTerminatedPrimary Progressive Nonfluent AphasiaCanada
-
University of California, Los AngelesRecruiting
-
Changping LaboratoryHenan Provincial People's Hospital; China Rehabilitation Research CenterRecruitingAutism Spectrum DisorderChina
-
Changping LaboratoryFujian Maternity and Child Health Hospital; Jining Medical University; Xi'an... and other collaboratorsNot yet recruitingAutism Spectrum Disorder